Humacyte, Inc. recently announced the presentation of results from the V007 phase 3 clinical trial of the company’s acel ...

R3 Vascular Inc. recently announced that the FDA granted investigational device exemption (IDE) approval to initiate the compa ...

November 11, 2024—iVascular announced the initiation of OPAL, a first-in-human study of Amber, the company’s embolic liquid ...

Akura Medical, a Shifamed portfolio company focused on venous thromboembolism care, announced recently that the FDA has approve ...

CVRx, Inc. announced recently that the Centers for Medicare and Medicaid Services (CMS) assigned the company’s Barostim p ...

In the LIFE-BTK trial, several initiatives were implemented to facilitate enrollment of diverse populations, ensuring that pati ...

DEEPER OUS is a prospective, nonrandomized, multicenter, single-arm trial taking place in New Zealand, Germany, and Switzerland ...

The final results from the DETOUR2 study evaluated the durability of percutaneous transmural arterial bypass (PTAB) using the D ...

A post hoc analysis of the SIRONA trial investigated how sirolimus-coated balloon angioplasty compares to various paclitaxel dr ...

Data from the STRIDE study suggest that race, not sex, is associated with outcomes in acute limb ischemia (ALI) treated with me ...

Two-year outcomes from the PROMISE II trial assessed transcatheter arterialization of the deep veins (TADV) using the LimFlow S ...

Investigators from the LIFE-BTK randomized controlled trial evaluating the use of the Drug-Eluting Resorbable Scaffold (Abbott) ...